Skip to main content

Table 2 Concentrations of sTNFR1 and neuropeptides in serum

From: Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis

Variable Early RA (pg/ml) Long-standing RA (pg/ml) P Controls (pg/ml)
sTNFR1 1500a 1900b ns 1200d
  (1300–1700) (1600–2000)   
BN/GRP 3000a 1700b <0.05 340e
  (2400–3300) (430–2500)   
CGRP 1500a 820b ns 310e
  (1100–1600) (510–1600)   
NPY 610a 900c ns 930f
  (370–890) (700–1900)   
SP 170a 410b <0.05 180g
  (150–300) (320–440)   
VIP 250a 280b ns 290g
  (210–280) (230–340)   
ESR 20a 32b ns nm
  (7 – 32) (22 – 47)   
  1. Concentrations were measured using ELISA. Values are medians (and Q1–Q3). The ESR is also shown. P relates to long-standing RA versus early RA. an = 4; bn = 22; cn = 21; dsTNFR1 value in healthy controls according to the manufacturer; en = 4; fn = 2; gn = 11. BN/GRP, bombesin/gastrin-releasing peptide; CGRP, calcitonin-gene-related peptide; ESR, erythrocyte sedimentation rate; NPY, neuropeptide Y; nm, not measured; ns, not significant; RA, rheumatoid arthritis; SP, substance P; sTNFR1, soluble tumour necrosis factor receptor 1; VIP, vasoactive intestinal peptide.